This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Global BioDiagnostics Receives Wellcome Trust Support For Development Of New TB Diagnostic

The new technique is already generating interest from public health authorities and NGOs active in South Africa, India and the Gulf States.

"We expect to develop our base in the UK at Sci-Tech Daresbury, near Liverpool, so that we can manage all aspects of the business from there, including global logistics and international relationship management," added Mr Norman.

TB is responsible for the deaths of some 1.4m people every year - or 3,800 people every day, half of them children - and is the world's eighth biggest killer according to the World Health Organisation. In 2009, there were almost 10 million orphan children as a result of the disease.

Sci-Tech Daresbury is a national science and innovation campus between Liverpool and Manchester which is regarded as one of Europe's leading centres for innovation and business. It assumed official status in April 2012 as one of the UK Government's flagship Enterprise Zones.

The site is a private-public sector joint venture between property company Langtree, the Science and Technology Facilities Council (STFC) and Halton Borough Council. The Universities of Lancaster, Liverpool and Manchester are active partners on the site.

John Downes, Group Chief Executive of Langtree and director of the Sci-Tech Daresbury Joint Venture Company, said: "Sci-Tech Daresbury's position at the heart of the UK's science and business community offers immeasurable assistance to businesses wishing to forge links with key partners such as the Wellcome Trust. We're delighted to be able to play a role in developing something which might have such an important impact on the lives of millions of people."  

NOTES TO EDITORS

About Global BioDiagnostics

Global BioDiagnostics Corp. is an early stage biotechnology company whose mission is to develop, manufacture and distribute diagnostics that address huge needs in the global infectious disease market. The company's first product in development for TB utilizes a ground-breaking biophotonic detection platform called Reporter Enzyme Fluorescence (REF) developed by researchers at Texas A&M Health Science Center College of Medicine and Stanford University.  The research conducted by Texas A&M and Stanford was funded by the Bill and Melinda Gates Foundation. The company has offices in Temple, Texas and Daresbury, England.

http://www.gbdbio.com

About Sci-Tech Daresbury

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,039.49 +60.36 0.36%
S&P 500 1,992.37 +5.86 0.30%
NASDAQ 4,532.1040 +5.6220 0.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs